The Division of Cardiovascular Medicine is committed to bringing the highest standard of cardiovascular care to our community, while also promoting scientific discovery and training the next generation of leaders in cardiovascular medicine.

Our patient care enterprise consists of physicians and staff that are dedicated to comprehensively addressing our patients’ needs in acute cardiovascular medical care, disease prevention, and education. We have embraced a team-based approach involving physicians, physicians’ assistants, nurse practitioners, critical care nurses and nurse educators, as well as nutritionists and behavioral counselors to provide the best possible outcomes to our patient population.

As an academic division, we also are committed to bringing cutting-edge technology and treatment to our patient community. Therefore, we have specialists in critical care, interventional cardiology, electrophysiology, prevention, and heart failure available at all times. We are a national leader in heart attack care and have the most advanced catheterization laboratory in the Commonwealth. State-of-the-art programs in catheter-based heart valve treatment, arrhythmia ablation, and outpatient coronary stent implantation have established us as the region’s leading provider of cutting-edge cardiovascular care.

Because we believe patient and community education is paramount to improving the cardiovascular health of our community, we have established multiple education programs. Most prominent is our cardiology fellowship program that graduates 6 next-generation cardiovascular specialists annually. We also provide community forums on common cardiovascular conditions and have patient education and support groups related to heart device implants, arrhythmias, and heart failure treatment.

As faculty in the medical school, we are also committed to advancing knowledge in the cardiovascular arena. As a consequence, we have internationally-recognized programs in vascular biology, thrombosis, gene therapy, cardiac development, and the role of micro RNA in cardiovascular disease. We also maintain a robust portfolio of clinical trials that provide our patients to opportunity to experience the latest in new treatments.